Moderna announces phase 1/2 data on mrna-3927, an investigational mrna therapy for propionic acidemia (pa) to be presented at the 2023 asgct annual meeting

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent dsmb, the phase 1/2 trial of mrna-3927 advances to the dose-expansion phase to determine a recommended dose cambridge, ma / accesswire / may 3, 2023 / moderna,inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that an abstract reporting on interim data from the phase 1/2 trial of mrna-3927, an investigational mrna therapy for propionic acidemia (pa) has been accepted for presentation at the 2023 american society of gene + cell therapy (asgct) annual meeting being held may 16-20, 2023 in los angeles, ca. the presentation details are as follows: title: mrna-3927 therapy for propionic acidemia: interim data from a phase 1/2 studysession: metabolic, storage, endocrine, liver, and gastrointestinal diseases ii date/time: thursday, may 18, 2023, 04:45 pm - 05:00 pm ptpresenter: gerald s.
MRNA Ratings Summary
MRNA Quant Ranking